FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022793570> ?p ?o ?g. }

• W2022793570 endingPage "374" @default.
• W2022793570 startingPage "364" @default.
• W2022793570 abstract "In Brief Purpose To characterize the safety profile of triamcinolone acetonide (TA) for intraocular application. Methods In vitro cell viability assay was performed on 2 types of human ocular cells to evaluate the cytotoxicity of the simulated different vitreal concentrations (from a 1:15 dilution as if injected into 1.5 mL of rabbit vitreous to 1:50 dilution as if injected into 5 mL of human vitreous) of preservative and excipient (supernatant) from Kenalog-40. In vivo 35 guinea pigs were used for evaluating either a dose of intravitreal triamcinolone acetonide (Kenalog-40 and Triesence) or the supernatant of Kenalog-40. The animal eyes were monitored by biomicroscopy, ophthalmoscopy, tonometry, electroretinography, and histology. Results A ≥1:15 dilution of triamcinolone acetonide supernatant from Kenalog-40 did not show cytotoxicity on cultured human pigment epithelial (retinal pigment epithelium) cells or Müller cells. In vivo, neither intravitreal 6 μL (0.248 mg, equivalent to 4 mg in 0.1 mL for human eyes) nor 18 μL (0.744 mg, equivalent to 4 mg in 0.1 mL for rabbit eyes and equivalent to 12 mg in 0.1 mL for human eyes) of triamcinolone acetonide suspension showed ocular toxicity. No significant difference was noted between Kenalog-40 and Triesence clinically and histopathologically. Conclusion The equivalent triamcinolone acetonide doses to 0.1 mL (4 or 12 mg) intravitreal injection for human eye were found safe in guinea pig eyes. No significant difference was noted for 0.1 mL intravitreal injection between Kenalog-40 and Triesence. Intravitreal triamcinolone acetonide at dose of ≤12 mg may not be toxic and 0.1-mL intravitreal injection of triamcinolone acetonide suspension without preservative decanting may be a safe practice." @default.
• W2022793570 created "2016-06-24" @default.
• W2022793570 creator A5006790399 @default.
• W2022793570 creator A5014934412 @default.
• W2022793570 creator A5017227883 @default.
• W2022793570 creator A5022499603 @default.
• W2022793570 creator A5030832104 @default.
• W2022793570 creator A5039407742 @default.
• W2022793570 creator A5045990965 @default.
• W2022793570 creator A5071795862 @default.
• W2022793570 creator A5079587373 @default.
• W2022793570 creator A5081541864 @default.
• W2022793570 date "2012-02-01" @default.
• W2022793570 modified "2023-09-26" @default.
• W2022793570 title "FURTHER CHARACTERIZATION OF OCULAR SAFETY PROFILE OF COMMERCIALLY AVAILABLE PRESERVED AND PRESERVATIVE-FREE TRIAMCINOLONE ACETONIDE" @default.
• W2022793570 cites W1965563034 @default.
• W2022793570 cites W1970485363 @default.
• W2022793570 cites W1970508873 @default.
• W2022793570 cites W1972147794 @default.
• W2022793570 cites W1974995859 @default.
• W2022793570 cites W1979544980 @default.
• W2022793570 cites W1981648891 @default.
• W2022793570 cites W1999573016 @default.
• W2022793570 cites W2001170297 @default.
• W2022793570 cites W2004935487 @default.
• W2022793570 cites W2021725605 @default.
• W2022793570 cites W2029607484 @default.
• W2022793570 cites W2032105712 @default.
• W2022793570 cites W2040415931 @default.
• W2022793570 cites W2046882887 @default.
• W2022793570 cites W2058120241 @default.
• W2022793570 cites W2063504478 @default.
• W2022793570 cites W2079254946 @default.
• W2022793570 cites W2082800242 @default.
• W2022793570 cites W2084959783 @default.
• W2022793570 cites W2087211548 @default.
• W2022793570 cites W2091438473 @default.
• W2022793570 cites W2098155102 @default.
• W2022793570 cites W2103657369 @default.
• W2022793570 cites W2124253560 @default.
• W2022793570 cites W2128533866 @default.
• W2022793570 cites W2132561513 @default.
• W2022793570 cites W2137743590 @default.
• W2022793570 cites W2148930693 @default.
• W2022793570 cites W2232176731 @default.
• W2022793570 cites W2468104700 @default.
• W2022793570 doi "https://doi.org/10.1097/iae.0b013e31821e1f7c" @default.
• W2022793570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21909054" @default.
• W2022793570 hasPublicationYear "2012" @default.
• W2022793570 type Work @default.
• W2022793570 sameAs 2022793570 @default.
• W2022793570 citedByCount "13" @default.
• W2022793570 countsByYear W20227935702012 @default.
• W2022793570 countsByYear W20227935702013 @default.
• W2022793570 countsByYear W20227935702014 @default.
• W2022793570 countsByYear W20227935702015 @default.
• W2022793570 countsByYear W20227935702016 @default.
• W2022793570 countsByYear W20227935702017 @default.
• W2022793570 countsByYear W20227935702019 @default.
• W2022793570 countsByYear W20227935702022 @default.
• W2022793570 countsByYear W20227935702023 @default.
• W2022793570 crossrefType "journal-article" @default.
• W2022793570 hasAuthorship W2022793570A5006790399 @default.
• W2022793570 hasAuthorship W2022793570A5014934412 @default.
• W2022793570 hasAuthorship W2022793570A5017227883 @default.
• W2022793570 hasAuthorship W2022793570A5022499603 @default.
• W2022793570 hasAuthorship W2022793570A5030832104 @default.
• W2022793570 hasAuthorship W2022793570A5039407742 @default.
• W2022793570 hasAuthorship W2022793570A5045990965 @default.
• W2022793570 hasAuthorship W2022793570A5071795862 @default.
• W2022793570 hasAuthorship W2022793570A5079587373 @default.
• W2022793570 hasAuthorship W2022793570A5081541864 @default.
• W2022793570 hasConcept C118487528 @default.
• W2022793570 hasConcept C141071460 @default.
• W2022793570 hasConcept C150903083 @default.
• W2022793570 hasConcept C185592680 @default.
• W2022793570 hasConcept C207001950 @default.
• W2022793570 hasConcept C2776251621 @default.
• W2022793570 hasConcept C2776804153 @default.
• W2022793570 hasConcept C2778903070 @default.
• W2022793570 hasConcept C2781092963 @default.
• W2022793570 hasConcept C71924100 @default.
• W2022793570 hasConcept C86803240 @default.
• W2022793570 hasConcept C98274493 @default.
• W2022793570 hasConceptScore W2022793570C118487528 @default.
• W2022793570 hasConceptScore W2022793570C141071460 @default.
• W2022793570 hasConceptScore W2022793570C150903083 @default.
• W2022793570 hasConceptScore W2022793570C185592680 @default.
• W2022793570 hasConceptScore W2022793570C207001950 @default.
• W2022793570 hasConceptScore W2022793570C2776251621 @default.
• W2022793570 hasConceptScore W2022793570C2776804153 @default.
• W2022793570 hasConceptScore W2022793570C2778903070 @default.
• W2022793570 hasConceptScore W2022793570C2781092963 @default.
• W2022793570 hasConceptScore W2022793570C71924100 @default.
• W2022793570 hasConceptScore W2022793570C86803240 @default.
• W2022793570 hasConceptScore W2022793570C98274493 @default.
• W2022793570 hasIssue "2" @default.
• W2022793570 hasLocation W20227935701 @default.

• next